ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study

Study limitation reported by the research below: “The ustekinumab comparator arm in Part 2 was small (n=28), reducing the power to detect differences in most outcomes other than PASI100.”

Papers